Latest news with #VELO
Daily Mail
30-06-2025
- General
- Daily Mail
Traveller left shocked after flight attendant demands plane passenger gets rid of popular item
A plane passenger left social media users shocked after revealing they were instructed by a flight attendant to 'spit out' a popular product used by a growing number of adults. In a post uploaded to the popular Reddit community, r/Delta, the passenger detailed their exchange on a Delta flight, adding that he complied 'right away' in getting rid of the item. The US-based flyer, who goes by u/Aquahammer, said that the item in question was a tobacco-free nicotine pouch. Marketed as a smoke-free alternative to traditional products, nicotine pouches are designed to be placed between the gum and lip, where nicotine is absorbed into the bloodstream. Brands such as ZYN, VELO, Nordic Spirit and Rogue have gained popularity in recent years, with roughly 1.1 per cent of British adults currently using nicotine pouches, while 6 per cent have tried them, according to Action on Smoking and Health. In the Reddit post, the passenger shared: 'Got told to spit my Zyn out on a flight, I really didn't know that was a thing? Delta flight, first class (not that that matters).' The person added: 'They brought a cup out and asked me to spit my zyn out. They said it was because it was a tobacco product. I didn't put up a fight and complied right away. Was just wondering if this was an FAA thing I didn't know about?' The post has since amassed over 80 comments as fellow Redditors shared their thoughts about using nicotine pouches during flights. One person wrote: 'Delta policy bans "smokeless tobacco" products. Zyn is of course not a smokeless tobacco product (no tobacco), but I wouldn't want to get pedantic with a flight attendant. So just be more sneaky about it next time.' However, another challenged: 'It's rather confusing. What constitutes a "smokeless product"? Are they implying smokeless tobacco products? Zyn, for instance, is not a tobacco product at all - its nicotine is synthetically derived. 'I also wonder why nicotine pouches are not allowed on flights. I understand chewing tobacco since you need to dispose of it in an unhygienic way. But nicotine pouches are unobtrusive, no less hygienic than gum, don't produce vapors or other noticeable smells...' A third contributor hit back: 'Tobacco or not, does it cause you to spit into a bottle or cup that could spill or be left stuffed in the seat pocket that someone else has to clean up? Then I'd say it doesn't matter what you call it.' One person warned the passenger: 'It's allowed but be discreet, I see many people using them on flights myself included and as long as you're not doing it right in front of an FA you're fine. However, one plane passenger shared: 'I had a FA confirm that Zyns are not allowed which is crazy. I was in Delta one and she told me they aren't allowed but she doesn't care. I think she just wanted me to hide it from the other FAs. I don't get it though.' A United Airlines flyer added: 'I was on a United flight a few days ago and the shopping/menu magazine in the seatback actually had a Zyn add in it. It said something like "Flight ready".' It comes after another plane passenger reignited an etiquette debate about wearing shoes and socks on flights in 2024. Sharing their thoughts on a post to Reddit, the user - who posted under MilitaryBaker - sparked a fierce debate over the matter. Posting to the Unpopular Opinion subreddit, the disgruntled flyer wrote: 'You should not be allowed to take off your shoes or socks on a plane.' 'Planes are already one of the most horribly smelling places you can be,' the user wrote. They went on to acknowledge that although it is more 'comfortable,' some people's feet are 'literally intolerable.'
Cision Canada
18-06-2025
- Business
- Cision Canada
Velo Protocol: Binance Alpha Listing Accelerates Asia's Web3 Liquidity Revolution
SINGAPORE, June 18, 2025 /CNW/ -- Velo Protocol (VELO), a pioneer of Web3 liquidity infrastructure in Asia, was listed on Binance Alpha on Monday, June 16, 2025. This listing not only increases $VELO's liquidity and connects its community to the global market, but also marks a strategic step in Velo Protocol's expansion roadmap to solidify its position as the backbone of Asia's digital financial ecosystem through significant milestones, an ambitious expansion roadmap, and visionary future project initiatives. In addition to the Binance Alpha Listing, The State of Velo Q1 2025 Report by Messari marks another important milestone for Velo Protocol. During Q1, average daily transactions surged 255.5%, rising from 445 to 1,581, driven by Nova network activity. Daily active addresses also increased 84.7%, from 2,363 to 4,364, while VELO-denominated TVL grew 10.1%. Backed by major institutions such as CP Group, UOB Venture Management, and HashKey, along with strategic collaborations with Paxos ($USDL) and Securitize to advance asset tokenization, Velo is building a compliant and scalable digital liquidity infrastructure across Asia. Unlocking New Financial Access in Asia Through its Universe and Orbit platforms, Velo has achieved multiple key milestones: Integration of the Lightyear Trading Bot with MT4, MT5, and Trading View, enhancing trading efficiency. SofinX-powered Social Trading feature that enables users to replicate top traders' strategies. Multi-chain support through integration with Solana and external wallets, expanding Universe DEX's reach. Omni Points loyalty program on Orbit delivering real multi-chain rewards. Surpassing 1 million Unique Active Wallets (UAW) on DAppRadar, signifying significant ecosystem growth. Major Expansion: Scaling Asia's Web3 Ecosystem With a vision to accelerate the transition from Web2 to Web3, Velo is introducing a series of innovations that significantly expand its ecosystem's capabilities. The Universe Platform will soon launch next-generation Multi FX and Perpetual (Perp) contracts, powered by a sophisticated Liquidity Aggregator that sources liquidity from multiple platforms. Meanwhile, the Profit-Sharing Social Trading feature enables users to benefit from automated trading bots or mirror the strategies of top-performing traders. To further enhance user experience, Multi-Chain & Wallet Connect integration allows seamless external wallet connectivity across multiple blockchains. Additionally, the Orbit Platform offers a Whitelabel Loyalty Platform, empowering businesses to adopt Web3-based loyalty programs with ease. Future Roadmap: Delivering Asia's Web3 Financial Infrastructure Collectively, these innovations serve as the foundation for Velo's long-term vision of building the Velo Financial Superhighway—a fully integrated Web3-native ecosystem aimed at driving financial inclusion across Asia. On the Liquidity Layer, Velo will feature the PLG Gold RWA Token for on-chain gold exposure, a Stable Coin and RWA Aggregator to strengthen trade stability, and a Web2 to Web3 Liquidity Backbone to bridge multi-chain liquidity. On the Wallet Layer, the Orbit-based Super Wallet will integrate payments and loyalty into a unified merchant ecosystem across Asia. On the Settlement Layer, Velo PAYFAI, an AI-based system that uses PayFi and AI agents to optimize settlement, will accelerate Web3-based cross-border trade financing, positioning Velo as a bridge asset in Asia's digital trade flows. The Binance Alpha listing and the Messari Report are not merely market expansion milestones, but a testament to the growing global confidence in Velo Protocol's technology, utility, and mission to bridge traditional and decentralized finance across Asia. This milestone further accelerates Velo Protocol's position as the backbone of Asia's liquidity infrastructure, powering the region's trillion-dollar digital economy. Velo Protocol is an Asia-based Web3 liquidity infrastructure bridging traditional and decentralized finance. With multi-chain technology, social trading, stablecoins, RWA, and AI-powered settlement, Velo is leading Asia's digital financial transformation. SOURCE Velo Labs Technology Ltd.
Business Upturn
06-06-2025
- Business
- Business Upturn
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]
Yahoo
06-06-2025
- Business
- Yahoo
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX DiagnosticsChris Holeenquires@ Scius CommunicationsKatja Stout+44 778 943 5990katja@ Daniel Gooch+44 774 787 5479daniel@ _____________________1 This LEX Diagnostics product is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available for sale or distribution in the U.S., the U.K. or any other jurisdiction. All product descriptions, data, or discussions are preliminary, subject to change, and do not represent final or FDA-approved claims, indications, or labeling.
Gulf Today
28-05-2025
- Health
- Gulf Today
British American Tobacco Middle East DMCC (BAT) hosts Tobacco Harm Reduction event in Dubai
Gulf Network British American Tobacco Middle East DMCC hosted an event today in Dubai to spotlight the role of innovation and science in advancing tobacco harm reduction (THR). The event coincided with the release of the UAE's first national standards for tobacco-free oral nicotine pouches – marking a significant step in establishing a framework for product quality, safety, and manufacturing. At the event, BAT Middle East North Africa (MENA) highlighted its ongoing transformation toward building A Better Tomorrow, with a commitment to providing adult smokers, who would otherwise continue to smoke, with a wide range of reduced-risk* alternatives to combustible cigarettes. BAT also introduced Omni, its evidence-based, dynamic resource that showcases how science and innovation are driving progress towards A Smokeless World. Omni, a resource intended for scientists, public health authorities, regulators, policy makers, and investors, brings together hundreds of independent scientific studies and research, BAT's own research into its innovation, as well as real-world examples of Tobacco Harm Reduction (THR) in action. One of the real-world examples highlighted at the event was Sweden's success in achieving the lowest smoking prevalence in the European Union. A key to Sweden's success has been its openness to allow the sale of smokeless alternatives to cigarettes that satisfy adult smokers' desire for nicotine, and to avoid excessively restricting these products. Local insights shared at the event further underscored the growing consumer openness to smokeless products to combustible cigarettes in the UAE. According to local internal research conducted by Kantar, 83% of adult smokers in the UAE are open to switching to reduced-risk* alternatives. Commenting on the occasion, Alexandre Ghanem, General Manager of BAT MENA, said, 'We are proud to contribute to conversations that support science-led transformation in our industry. The availability of nicotine alternatives, supported by regulation, innovation, and evidence, is key to encouraging a complete switch among adult smokers who would otherwise continue smoking.' Showcasing Omni to the UAE audience for the first time, Mark Forster, BAT Group's Senior Scientific Engagement Manager, added: 'We believe that Tobacco Harm Reduction represents one of the most significant public health opportunities. Especially as we near World No Tobacco Day, we stand alongside those calling for well-thought-out regulations that can help countries achieve their smoke-free ambition by encouraging adult smokers, who would otherwise continue smoking, to switch completely to smokeless alternatives, while preventing underage use.' BAT's tobacco-free nicotine pouches are already available in over 40 countries. The company has plans to expand its smokeless product portfolio in the UAE under the flagship nicotine pouch brand VELO. *Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
